Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
Int J Pharm. 2020 Apr 30;580:119190. doi: 10.1016/j.ijpharm.2020.119190. Epub 2020 Mar 6.
Cisplatin is one of the most widely used platinum-based anticancer chemotherapeutic drugs. However, its low solubility, serious side effects and the development of cisplatin resistance limit its further use in the clinic. Controlling the delivery and release of cisplatin at the targeted site efficiently is a meaningful way to overcome these undesirable side effects of cisplatin. Herein, a tumor targeted and stimuli responsive nano-delivery system for cisplatin was constructed using branched polyethyleneimine (BPEI) as the backbone, disulfide bond as the redox-responsive covalent linker and hyaluronic acid (HA) as targeting recognition unit which can bind selectively to the receptor of CD44, which is highly expressed on the A549 tumor cells. The cisplatin-polyethyleneimine conjugate BPEI-SS-Pt was prepared and the drug loading of cisplatin was up to 32.66 ± 0.06%. After optimized the coating weight ratio of HA and BPEI-SS-Pt, the nanoparticle delivery system HA-(BPEI-SS-Pt)-1/4 outperformed with smaller particle size of 159.0 ± 21.0 nm, narrow polydispersity index (PDI) of 0.069 ± 0.022 and higher cisplatin loading of 29.23 ± 0.18%, showing specific tumor-targeting ability and redox-responsive drug release manner. Moreover, for the treatment of cancer in vivo, it achieved more effective antitumor performance along with minor side effects and systemic toxicity compared with cisplatin which is of great significance for the chemotherapeutic drug in the clinic.
顺铂是最广泛使用的铂类抗癌化疗药物之一。然而,其低溶解度、严重的副作用和顺铂耐药性的发展限制了其在临床上的进一步应用。在靶部位有效控制顺铂的传递和释放是克服顺铂这些不良副作用的一种有意义的方法。在此,构建了一种基于支化聚乙烯亚胺(BPEI)为骨架、二硫键为氧化还原响应性共价连接体、透明质酸(HA)为靶向识别单元的肿瘤靶向和刺激响应型纳米递药系统,HA 可以选择性地与 CD44 受体结合,CD44 受体在 A549 肿瘤细胞上高度表达。制备了顺铂-聚乙烯亚胺缀合物 BPEI-SS-Pt,其载药量高达 32.66±0.06%。在优化了 HA 和 BPEI-SS-Pt 的包被重量比后,纳米粒递药系统 HA-(BPEI-SS-Pt)-1/4 表现出更小的粒径 159.0±21.0nm、更窄的多分散指数(PDI)0.069±0.022 和更高的顺铂载药量 29.23±0.18%,表现出特异性的肿瘤靶向能力和氧化还原响应性药物释放方式。此外,在体内治疗癌症方面,与顺铂相比,它具有更小的副作用和全身毒性,实现了更有效的抗肿瘤性能,这对临床化疗药物具有重要意义。